Evidence map›Paper›PMID 29610202›Full record

ArticleAntimicrobial agents and chemotherapy2018

Tarani Kanta Barman, Manoj Kumar, Tarun Mathur, Eiko Namba, Diksha Singh, Tridib Chaira, Yuichi Kurosaka, Makiko Yamada, Dilip Jatashankar Upadhyay, Nobuhisa Masuda

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. The Urgent Threat ofBiomedicines · 2023
    Review
  2. Discovery ofJournal of enzyme inhibition and medicinal chemistry · 2022
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Tarani Kanta Barman *Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Manoj Kumar *Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Tarun Mathur *Department of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Eiko NambaDaiichi Sankyo Co., Ltd., Tokyo, Japan.
Diksha SinghDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Tridib ChairaDepartment of Pharmacokinetics and Metabolism, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Yuichi KurosakaDaiichi Sankyo Co., Ltd., Tokyo, Japan.
Makiko YamadaDaiichi Sankyo Co., Ltd., Tokyo, Japan.
Dilip Jatashankar UpadhyayDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India.
Nobuhisa MasudaDepartment of Microbiology, Daiichi Sankyo India Pharma Private Limited, Gurgaon, Haryana, India masuda.nobuhisa.up@daiichisankyo.co.jp.
Daiichi Sankyo (India) · INDaiichi-Sankyo (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DS-2969b is a novel GyrB inhibitor under clinical development. In this study, the

Indexed as

AnimalsAnti-Bacterial AgentsDNA GyraseFemaleHaemophilus influenzaeMethicillin-Resistant Staphylococcus aureusMiceMicrobial Sensitivity TestsMolecular StructureMoraxella catarrhalisPneumonia, StaphylococcalProdrugsStaphylococcus aureusAnti-Bacterial AgentsDNA GyraseProdrugsanimal modelsDNA gyrasemethicillin resistancepharmacodynamicspharmacokineticsStaphylococcus aureus

Identifiers

PMID29610202
PMCPMC5971602
OpenAlexW2795834568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.